18.75
-0.75 (-3.85%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Phathom Pharmaceuticals, Inc. | Mixed | Bullish |
Stockmoo Score
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Jun 2024 | 7,464,572 |
| Checkpoint Capital L.P. | 30 Jun 2024 | 875,000 |
| Propel Bio Management, Llc | 30 Jun 2024 | 869,927 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (HC Wainwright & Co., 49.33%) | Buy |
| Median | 26.00 (38.67%) | |
| Low | 12.00 (Goldman Sachs, -36.00%) | Hold |
| Average | 22.00 (17.33%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 14.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 Sep 2024 | 26.00 (38.67%) | Buy | 18.30 |
| 06 Sep 2024 | 26.00 (38.67%) | Buy | 17.72 | |
| HC Wainwright & Co. | 12 Aug 2024 | 28.00 (49.33%) | Buy | 12.03 |
| 19 Jul 2024 | 28.00 (49.33%) | Buy | 10.95 | |
| Goldman Sachs | 09 Aug 2024 | 12.00 (-36.00%) | Hold | 11.75 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2024 | Announcement | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 19 Aug 2024 | Announcement | Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants |
| 08 Aug 2024 | Announcement | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update |
| 30 Jul 2024 | Announcement | Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients |
| 29 Jul 2024 | Announcement | Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 |
| 18 Jul 2024 | Announcement | Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |